Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies
Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to impro...
Gespeichert in:
| Veröffentlicht in: | European archives of psychiatry and clinical neuroscience 2023-09, Vol.273 (6), p.1317-1328 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1328 |
|---|---|
| container_issue | 6 |
| container_start_page | 1317 |
| container_title | European archives of psychiatry and clinical neuroscience |
| container_volume | 273 |
| creator | Sapienza, Jacopo Spangaro, Marco Guillemin, Gilles J. Comai, Stefano Bosia, Marta |
| description | Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to improve cognitive outcome. Mounting evidence has shown the involvement of the kynurenine pathway in the pathophysiology of schizophrenia, also concerning cognitive symptoms. Therefore, the action of specific metabolites of kynurenine could affects cognition in schizophrenia. To evaluate the impact of the metabolites of kynurenine pathway on cognitive functions in schizophrenia spectrum disorders, with a focus on the modulating role of gender, to identify predictors of cognitive functioning and hypothetical pharmacological targets able to resize disability by improving cognition, thus functioning and quality of life. A systematic review was performed in PubMed/MEDLINE and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies measuring the direct impact of kynurenine metabolites on cognitive performances in living individuals with schizophrenia spectrum disorders were included in the review. Six studies were included. The activation of the kynurenine pathway resulted associated with greater cognitive deficits in patients with schizophrenia and both elevations and reduction of metabolites seemed able to affect cognitive outcome. No modulating role of sex emerged. This systematic review provides evidence that the activation of the kynurenine pathway affects cognition in patients with schizophrenia and highlights this pathway as a possible future target for developing novel drugs toward this still unmet clinical need. However, evidence is still limited and future studies are needed to further clarify the relationship between kynurenine pathway and cognition in schizophrenia. |
| doi_str_mv | 10.1007/s00406-022-01519-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2746389569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A762138491</galeid><sourcerecordid>A762138491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-12b2de2e119239000f938f2839783d5beb073ca7488ad59c07ed775450b64c273</originalsourceid><addsrcrecordid>eNp9kc2L1TAUxYso-Bz9B1wF3LjpePPRpnE3DH4MDLjRdchLb9_L2CY1SR06K_9003nKoIjcxYWb3zkccqrqJYVzCiDfJAABbQ2M1UAbqmp4VO2o4LzuhKKPqx0oATXlXDytnqV0A1AwBrvqx9U0h5iNt0jCQPIRSb-miIdlNNkF__v4dfVLRO88ktnk461ZSXm04eDdPeY8Sfbo7sJ83DDzlhiS1pRxKjaWRPzu8HYzs6PzzpqRpLz0DtPz6slgxoQvfu2z6sv7d58vP9bXnz5cXV5c11ZQlWvK9qxHhpQqxlWJPyjeDazjSna8b_a4B8mtkaLrTN8oCxJ7KRvRwL4Vlkl-Vr0--c4xfFswZT25ZHEcjcewJM2kaHmnmlYV9NVf6E1Yoi_pNOuathWSAXugDmZE7fwQcjR2M9UXsmWUbz9fqPN_UGV6nJwNHgdX7n8I2ElgY0iliEHP0U0mrpqC3rrWp6516Vrfd62hiPhJlArsDxgfEv9H9RO2vauw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2856647202</pqid></control><display><type>article</type><title>Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies</title><source>SpringerLink Journals - AutoHoldings</source><creator>Sapienza, Jacopo ; Spangaro, Marco ; Guillemin, Gilles J. ; Comai, Stefano ; Bosia, Marta</creator><creatorcontrib>Sapienza, Jacopo ; Spangaro, Marco ; Guillemin, Gilles J. ; Comai, Stefano ; Bosia, Marta</creatorcontrib><description>Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to improve cognitive outcome. Mounting evidence has shown the involvement of the kynurenine pathway in the pathophysiology of schizophrenia, also concerning cognitive symptoms. Therefore, the action of specific metabolites of kynurenine could affects cognition in schizophrenia. To evaluate the impact of the metabolites of kynurenine pathway on cognitive functions in schizophrenia spectrum disorders, with a focus on the modulating role of gender, to identify predictors of cognitive functioning and hypothetical pharmacological targets able to resize disability by improving cognition, thus functioning and quality of life. A systematic review was performed in PubMed/MEDLINE and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies measuring the direct impact of kynurenine metabolites on cognitive performances in living individuals with schizophrenia spectrum disorders were included in the review. Six studies were included. The activation of the kynurenine pathway resulted associated with greater cognitive deficits in patients with schizophrenia and both elevations and reduction of metabolites seemed able to affect cognitive outcome. No modulating role of sex emerged. This systematic review provides evidence that the activation of the kynurenine pathway affects cognition in patients with schizophrenia and highlights this pathway as a possible future target for developing novel drugs toward this still unmet clinical need. However, evidence is still limited and future studies are needed to further clarify the relationship between kynurenine pathway and cognition in schizophrenia.</description><identifier>ISSN: 0940-1334</identifier><identifier>EISSN: 1433-8491</identifier><identifier>DOI: 10.1007/s00406-022-01519-0</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Amino acids ; Clinical trials ; Cognition & reasoning ; Cognitive ability ; Invited Review ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Memory ; Mental disorders ; Metabolites ; Neurophysiology ; Neurosciences ; Psychiatry ; Quality of life ; Schizophrenia ; Systematic review</subject><ispartof>European archives of psychiatry and clinical neuroscience, 2023-09, Vol.273 (6), p.1317-1328</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>COPYRIGHT 2023 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-12b2de2e119239000f938f2839783d5beb073ca7488ad59c07ed775450b64c273</citedby><cites>FETCH-LOGICAL-c419t-12b2de2e119239000f938f2839783d5beb073ca7488ad59c07ed775450b64c273</cites><orcidid>0000-0002-5686-7194</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00406-022-01519-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00406-022-01519-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Sapienza, Jacopo</creatorcontrib><creatorcontrib>Spangaro, Marco</creatorcontrib><creatorcontrib>Guillemin, Gilles J.</creatorcontrib><creatorcontrib>Comai, Stefano</creatorcontrib><creatorcontrib>Bosia, Marta</creatorcontrib><title>Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies</title><title>European archives of psychiatry and clinical neuroscience</title><addtitle>Eur Arch Psychiatry Clin Neurosci</addtitle><description>Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to improve cognitive outcome. Mounting evidence has shown the involvement of the kynurenine pathway in the pathophysiology of schizophrenia, also concerning cognitive symptoms. Therefore, the action of specific metabolites of kynurenine could affects cognition in schizophrenia. To evaluate the impact of the metabolites of kynurenine pathway on cognitive functions in schizophrenia spectrum disorders, with a focus on the modulating role of gender, to identify predictors of cognitive functioning and hypothetical pharmacological targets able to resize disability by improving cognition, thus functioning and quality of life. A systematic review was performed in PubMed/MEDLINE and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies measuring the direct impact of kynurenine metabolites on cognitive performances in living individuals with schizophrenia spectrum disorders were included in the review. Six studies were included. The activation of the kynurenine pathway resulted associated with greater cognitive deficits in patients with schizophrenia and both elevations and reduction of metabolites seemed able to affect cognitive outcome. No modulating role of sex emerged. This systematic review provides evidence that the activation of the kynurenine pathway affects cognition in patients with schizophrenia and highlights this pathway as a possible future target for developing novel drugs toward this still unmet clinical need. However, evidence is still limited and future studies are needed to further clarify the relationship between kynurenine pathway and cognition in schizophrenia.</description><subject>Amino acids</subject><subject>Clinical trials</subject><subject>Cognition & reasoning</subject><subject>Cognitive ability</subject><subject>Invited Review</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Memory</subject><subject>Mental disorders</subject><subject>Metabolites</subject><subject>Neurophysiology</subject><subject>Neurosciences</subject><subject>Psychiatry</subject><subject>Quality of life</subject><subject>Schizophrenia</subject><subject>Systematic review</subject><issn>0940-1334</issn><issn>1433-8491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kc2L1TAUxYso-Bz9B1wF3LjpePPRpnE3DH4MDLjRdchLb9_L2CY1SR06K_9003nKoIjcxYWb3zkccqrqJYVzCiDfJAABbQ2M1UAbqmp4VO2o4LzuhKKPqx0oATXlXDytnqV0A1AwBrvqx9U0h5iNt0jCQPIRSb-miIdlNNkF__v4dfVLRO88ktnk461ZSXm04eDdPeY8Sfbo7sJ83DDzlhiS1pRxKjaWRPzu8HYzs6PzzpqRpLz0DtPz6slgxoQvfu2z6sv7d58vP9bXnz5cXV5c11ZQlWvK9qxHhpQqxlWJPyjeDazjSna8b_a4B8mtkaLrTN8oCxJ7KRvRwL4Vlkl-Vr0--c4xfFswZT25ZHEcjcewJM2kaHmnmlYV9NVf6E1Yoi_pNOuathWSAXugDmZE7fwQcjR2M9UXsmWUbz9fqPN_UGV6nJwNHgdX7n8I2ElgY0iliEHP0U0mrpqC3rrWp6516Vrfd62hiPhJlArsDxgfEv9H9RO2vauw</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Sapienza, Jacopo</creator><creator>Spangaro, Marco</creator><creator>Guillemin, Gilles J.</creator><creator>Comai, Stefano</creator><creator>Bosia, Marta</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5686-7194</orcidid></search><sort><creationdate>20230901</creationdate><title>Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies</title><author>Sapienza, Jacopo ; Spangaro, Marco ; Guillemin, Gilles J. ; Comai, Stefano ; Bosia, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-12b2de2e119239000f938f2839783d5beb073ca7488ad59c07ed775450b64c273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Amino acids</topic><topic>Clinical trials</topic><topic>Cognition & reasoning</topic><topic>Cognitive ability</topic><topic>Invited Review</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Memory</topic><topic>Mental disorders</topic><topic>Metabolites</topic><topic>Neurophysiology</topic><topic>Neurosciences</topic><topic>Psychiatry</topic><topic>Quality of life</topic><topic>Schizophrenia</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sapienza, Jacopo</creatorcontrib><creatorcontrib>Spangaro, Marco</creatorcontrib><creatorcontrib>Guillemin, Gilles J.</creatorcontrib><creatorcontrib>Comai, Stefano</creatorcontrib><creatorcontrib>Bosia, Marta</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>European archives of psychiatry and clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sapienza, Jacopo</au><au>Spangaro, Marco</au><au>Guillemin, Gilles J.</au><au>Comai, Stefano</au><au>Bosia, Marta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies</atitle><jtitle>European archives of psychiatry and clinical neuroscience</jtitle><stitle>Eur Arch Psychiatry Clin Neurosci</stitle><date>2023-09-01</date><risdate>2023</risdate><volume>273</volume><issue>6</issue><spage>1317</spage><epage>1328</epage><pages>1317-1328</pages><issn>0940-1334</issn><eissn>1433-8491</eissn><abstract>Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to improve cognitive outcome. Mounting evidence has shown the involvement of the kynurenine pathway in the pathophysiology of schizophrenia, also concerning cognitive symptoms. Therefore, the action of specific metabolites of kynurenine could affects cognition in schizophrenia. To evaluate the impact of the metabolites of kynurenine pathway on cognitive functions in schizophrenia spectrum disorders, with a focus on the modulating role of gender, to identify predictors of cognitive functioning and hypothetical pharmacological targets able to resize disability by improving cognition, thus functioning and quality of life. A systematic review was performed in PubMed/MEDLINE and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies measuring the direct impact of kynurenine metabolites on cognitive performances in living individuals with schizophrenia spectrum disorders were included in the review. Six studies were included. The activation of the kynurenine pathway resulted associated with greater cognitive deficits in patients with schizophrenia and both elevations and reduction of metabolites seemed able to affect cognitive outcome. No modulating role of sex emerged. This systematic review provides evidence that the activation of the kynurenine pathway affects cognition in patients with schizophrenia and highlights this pathway as a possible future target for developing novel drugs toward this still unmet clinical need. However, evidence is still limited and future studies are needed to further clarify the relationship between kynurenine pathway and cognition in schizophrenia.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00406-022-01519-0</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-5686-7194</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0940-1334 |
| ispartof | European archives of psychiatry and clinical neuroscience, 2023-09, Vol.273 (6), p.1317-1328 |
| issn | 0940-1334 1433-8491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2746389569 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Amino acids Clinical trials Cognition & reasoning Cognitive ability Invited Review Medical research Medicine Medicine & Public Health Medicine, Experimental Memory Mental disorders Metabolites Neurophysiology Neurosciences Psychiatry Quality of life Schizophrenia Systematic review |
| title | Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A39%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Importance%20of%20the%20dysregulation%20of%20the%20kynurenine%20pathway%20on%20cognition%20in%20schizophrenia:%20a%20systematic%20review%20of%20clinical%20studies&rft.jtitle=European%20archives%20of%20psychiatry%20and%20clinical%20neuroscience&rft.au=Sapienza,%20Jacopo&rft.date=2023-09-01&rft.volume=273&rft.issue=6&rft.spage=1317&rft.epage=1328&rft.pages=1317-1328&rft.issn=0940-1334&rft.eissn=1433-8491&rft_id=info:doi/10.1007/s00406-022-01519-0&rft_dat=%3Cgale_proqu%3EA762138491%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2856647202&rft_id=info:pmid/&rft_galeid=A762138491&rfr_iscdi=true |